Sfoglia per Autore
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells
2001 W. Carson, R. Parihar, M. Lindemann, N. Personeni, J. Dierksheide, N. Meropol, J. Baselga, M. Caligiuri
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
2003 C. Bozzetti, N. Personeni, R. Nizzoli, A. Guazzi, M. Flora, C. Bassano, F. Negri, E. Martella, N. Naldi, V. Franciosi, S. Cascinu
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer
2005 N. Personeni, A. Hendlisz, A. Gallez, M. Gomez Galdon, D. Larsimont, J. Van Laethem, N. Nagy, M. Barette, M. Paesmans, F. Cardoso, H. Bleiberg
Response prediction to EGFR-targeted therapies in colorectal cancer
2006 N. Personeni, T. S, V.C. E.
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes
2006 A. Hendlisz, N. Personeni, T. Delaunoit, S. Debroux, P. Flamen
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity
2006 C. Bozzetti, A. Musolino, R. Camisa, G. Bisagn, M. Flora, C. Bassano, E. Martella, C. Lagrasta, R. Nizzoli, N. Personeni, F. Leonardi, G. Cocconi, A. Ardizzoni
Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib : does intratumoral heterogeneity matter?
2006 N. Personeni
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer
2007 C. M, A. E, N. Personeni, L. F, P. Mj, C. F.
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas : can we improve epidermal growth factor receptor and phospho-AKT testing?
2007 N. Personeni
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
2008 W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, Van Laethem Jl, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study
2008 N. Personeni, S. Fieuws, H. Piessevaux, G. De Hertogh, J. De Schutter, B. Biesmans, W. De Roock, A. Capoen, M. Debiec Rychter, J. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy
2010 A. Hendlisz, M. Van Den Eynde, M. Peeters, G. Maleux, B. Lambert, J. Vannoote, K. De Keukeleire, C. Verslype, L. Defreyne, E. Van Cutsem, P. Delatte, T. Delaunoit, N. Personeni, M. Paesmans, J. Van Laethem, P. Flamen
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
2010 A. Santoro, T. Pressiani, G. Citterio, G. Rossoni, G. Donadoni, F. Pozzi, L. Rimassa, N. Personeni, S. Bozzarelli, G. Rossoni, S. Colombi, F.G. De Braud, F. Caligaris Cappio, A. Lambiase, C. Bordignon
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough?
2011 N. Personeni, G. Torzilli, A. Santoro
Fatal Infusion Reaction to Cetuximab : The Need for Predictive Risk Factors and Safer Patient Selection
2011 M.C. Tronconi, F. Sclafani, L. Rimassa, C. Carnaghi, N. Personeni, A. Santoro
Reply to Y. Pointreau et al
2012 M. Tronconi, F. Sclafani, L. Rimassa, C. Carnaghi, N. Personeni, A. Santoro
Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study
2012 A. Sartore Bianchi, S. Fieuws, S. Veronese, M. Moroni, N. Personeni, M. Frattini, V. Torri, F. Cappuzzo, S. Vander Borght, V. Martin, M. Skokan, A. Santoro, M. Gambacorta, S. Tejpar, M. Varella Garcia, S. Siena
Biomarkers in hepatocellular carcinoma - Letter
2012 N. Personeni, L. Rimassa, A. Santoro
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
2012 N. Personeni, S. Bozzarelli, T. Pressiani, L. Rimassa, M.C. Tronconi, F. Sclafani, C. Carnaghi, V. Pedicini, L. Giordano, A. Santoro
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma
2013 L. Rimassa, T. Pressiani, C. Boni, C. Carnaghi, E. Rota Caremoli, S. Fagiuoli, P. Foa, S. Salvagni, E. Cortesi, M.C. Tronconi, N. Personeni, S. Bozzarelli, M.C. Banzi, S. Fanello, F. Romano Lutman, L. Giordano, A. Santoro
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile